Kolon Life Science Inc. (KOSDAQ:102940)

Market Cap	597.60B
Revenue (ttm)	211.13B
Net Income (ttm)	17.80B
Shares Out	12.91M
EPS (ttm)	1,290.73
PE Ratio	35.87
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,729
Average Volume	65,712
Open	47,350
Previous Close	46,300
Day's Range	46,300 - 48,550
52-Week Range	21,050 - 61,900
Beta	-0.19
RSI	47.78
Earnings Date	Mar 17, 2026

About Kolon Life Science

Kolon Life Science Inc., a biotechnology company, develops cell and gene therapy products. The company is developing KLS-2031, a product candidate in Phase 1 clinical trials for use in the treatment of neuropathic pain; and KLS-3021, a oncolytic viral therapy in pre-clinical development. It also provides active pharmaceutical ingredients and pharmaceutical intermediates; offers CDMO and CMO services; and supplies pyrithione antimicrobial for use in personal care and industrials products. The company was formerly known as Korea Tissuegene Asia, ...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2000
• Employees: 322
• Stock Exchange: KOSDAQ
• Ticker Symbol: 102940

Financial Performance

In 2024, Kolon Life Science's revenue was 161.39 billion, an increase of 29.48% compared to the previous year's 124.64 billion. Losses were -93.09 billion, 203.0% more than in 2023.